Ansuman T. Satpathy
A5055604014- CAR-T cell therapy research
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Single-cell and spatial transcriptomics
- Immunotherapy and Immune Responses
- CRISPR and Genetic Engineering
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Immune cells in cancer
- Biosimilars and Bioanalytical Methods
- Genomics and Chromatin Dynamics
- Epigenetics and DNA Methylation
- Transgenic Plants and Applications
- Acute Myeloid Leukemia Research
- RNA modifications and cancer
- Immune Response and Inflammation
- Cytomegalovirus and herpesvirus research
- Cancer-related molecular mechanisms research
- RNA Research and Splicing
- SARS-CoV-2 and COVID-19 Research
- IL-33, ST2, and ILC Pathways
- Virus-based gene therapy research
- interferon and immune responses
- Diabetes and associated disorders
- Nanowire Synthesis and Applications
Stanford University
2016-2025
Gladstone Institutes
2022-2025
Parker Institute for Cancer Immunotherapy
2019-2025
Palo Alto University
2020-2024
University of California, San Francisco
2023-2024
Stratford University
2020-2023
Stone Clinic
2023
Stanford Cancer Institute
2018-2022
Immunai (United States)
2020
Washington University in St. Louis
2010-2019
CRISPR-Cas9 gene editing provides a powerful tool to enhance the natural ability of human T cells fight cancer. We report first-in-human phase 1 clinical trial test safety and feasibility multiplex engineer in three patients with refractory Two genes encoding endogenous cell receptor (TCR) chains, TCRα (
Cancer chromatin accessibility landscape The Genome Atlas (TCGA) provides a high-quality resource of molecular data on large variety human cancers. Corces et al. used recently modified assay to profile determine the accessible in 410 TCGA samples from 23 cancer types (see Perspective by Taipale). When were integrated with other omics available for same tumor samples, inherited risk loci predisposition revealed, transcription factors and enhancers driving subtypes patient survival differences...
Distinguishing dendritic cells (DCs) from other of the mononuclear phagocyte system is complicated by shared expression cell surface markers such as CD11c. In this study, we identified Zbtb46 (BTBD4) a transcription factor selectively expressed classical DCs (cDCs) and their committed progenitors but not plasmacytoid (pDCs), monocytes, macrophages, or lymphoid myeloid lineages. Using homologous recombination, replaced first coding exon with GFP to inactivate locus while allowing detection...
CAR-T cells rest to get back in the race Chimeric antigen receptor (CAR)–T cells, which are engineered target specific tumor antigens, increasingly used as an immunotherapy. have shown promising results patients, particularly hematologic cancers, but their anticancer activity can be limited by onset of exhaustion and loss effectiveness. Weber et al. characterized phenotypic epigenomic changes associated with cell caused continuous beneficial effects transient periods (see Perspective...